Global Reagents Markets Project Strong Growth Through 2033
Biotech reagents market projected to hit $148.21B by 2030; life science reagents to reach $114.4B by 2033. Growth driven by precision diagnostics, genomics, and personalized medicine.
Danaher Corporation
CompanyAlso known as: Danaher
Company Profile
Danaher is an American healthcare and life-sciences company developing products across biotechnology, diagnostics, and related scientific markets. Headquartered in Washington, D.C., it operates globally through multiple divisions and subsidiaries. The company is publicly traded on the NYSE under DHR.
- Website
- https://www.danaher.com
- Headquarters
- Washington, D.C., US
- Founded
- 1984
- Stock Ticker
- NYSE:DHR
Related News
CRISPR Technology Advances: Off-Target Benchmark, New Data, and Licensing Deal
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Thermo Fisher Raises Guidance; Danaher's Recovery Uneven in Mixed Results
Thermo Fisher posted 10% revenue growth in Q2 and raised guidance; Danaher's Q1 revenue missed but EPS beat. Danaher cited bioprocessing and life sciences strength and expects growth to accelerate.
Revvity Raises Outlook After Strong Q2, Launches New Drug Discovery Platforms
Revvity beat Q2 expectations, raised its full-year outlook, and launched new drug discovery platforms at SLAS2026. Revenue totaled $711 million with 3% organic growth.
Virus Filters Markets Poised for Strong Growth Through 2035 on Biologics Demand
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
Anterior Raises $40M to Accelerate Health Plan AI; Health Tech Funding Surges
Anterior raised $40M to accelerate health plan AI adoption, bringing total funding to $64M. Other deals include Findhelp's $250M investment, Grow Therapy's $150M Series D, and Bexorg's $23M Series A.
Omics Markets Projected Strong Growth Across Clinical Trials, Digital PCR Consumables, and Fluidic Samplers
Market reports project growth in omics-based clinical trials, Asia digital PCR consumables, and multi-omic fluidic samplers. The clinical trials market is set to reach $47.78B by 2030; fluidic samplers grow to $2.76B by 2036.
Danaher to buy Masimo in $9.9 billion diagnostics deal
Danaher agreed to acquire Masimo for $9.9 billion, paying $180 per share to expand its diagnostics portfolio into blood oxygen monitoring and patient monitoring devices. Danaher also launched nearly €3 billion in senior notes to help fund the deal, which is expected to close by the second half of 2026.
mRNA Synthesis and Manufacturing Market Seen Reaching $2.96 Billion by 2029
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Danaher guides for 3% to 6% 2026 growth as biotech funding shows signs of stabilizing
Danaher guided for 3% to 6% revenue growth and adjusted EPS of $8.35 to $8.50 in 2026 as biopharma spending shows signs of recovery. Recent results included $6.8 billion in quarterly sales, 2.5% core revenue growth and $1.8 billion in free cash flow.